Drug Type Universal CAR-T |
Synonyms Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy(Gracell Biotechnologies) |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD7 modulators(T-cell antigen CD7 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Phase 2 | CN | 31 Jan 2020 | |
Pre B-cell acute lymphoblastic leukemia | Phase 2 | CN | 31 Jan 2020 |